行情

CYAD

CYAD

Celyad Oncology
NASDAQ

实时行情|Nasdaq Last Sale

7.60
-0.13
-1.68%
已收盘, 16:00 03/03 EST
开盘
7.61
昨收
7.73
最高
7.71
最低
7.50
成交量
4,258
成交额
--
52周最高
13.01
52周最低
4.100
市值
1.06亿
市盈率(TTM)
-3.1569
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
到2026年,CAR-T细胞疗法的市场规模,份额和分析将以34.5%的复合年增长率增长,达到89.2亿美元
Feb 23, 2021 (Market Insight Reports) -- Selbyville, Delaware. The report CAR-T Cell Therapy Market Size and Analysis maintains enhanced dynamics and is...
Market Insight Reports · 02/23 10:42
嵌合抗原受体(CAR)T细胞疗法的市场份额,规模,增长机会,全球竞争策略,统计数据,行业趋势,收入分析,主要参与者,到2025年预测的区域分析
Feb 19, 2021 (The Expresswire) -- Global Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Research report discusses the market growth drivers and...
The Express Wire · 02/19 05:54
Celyad(CYAD)得到威廉·布莱尔的买入评级
William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD) today. The company's shares closed last Friday at $8.14. According to
SmarterAnalyst · 02/16 09:55
心肌梗塞药物市场2021年SWOT分析,关键业务战略,领先的行业参与者,区域增长,需求,份额,挑战,机遇和2027年预测研究报告
Feb 16, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Myocardial Infarction Drug...
The Express Wire · 02/16 07:01
Roots Analysis称,T细胞免疫疗法市场预计将以12.2%的年增长率增长
London, Feb 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- London, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of "Global T-Cell...
GlobeNewswire · 02/11 17:03
在2021-2026年期间,欧洲细胞和基因疗法市场的收入预计将以超过23%的复合年增长率增长
New York, Feb 10, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...
GlobeNewswire · 02/10 12:35
Stem Cell Reconstructive Market Size 2021 By Analysis, Manufacturers, Regions, Type and Application, and Forecasts to 2023
Heraldkeepers · 02/08 16:11
按疗法类型,目标适应症,目标抗原,主要参与者和主要地区划分的全球T细胞疗法市场-2020-2030年全球预测
New York, Feb 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...
GlobeNewswire · 02/05 12:29
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解CYAD最新的财务预测,通过CYAD每股收益,每股净资产,每股现金流等数据分析Celyad Oncology近期的经营情况,然后做出明智的投资选择。
分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CYAD价格均价为17.52,最高价位19.84,最低价为14.88。
EPS
机构持股
总机构数: 14
机构持股: 83.00万
持股比例: 5.95%
总股本: 1,394.23万
类型机构数股数
增持
0
0
建仓
2
-1.26万
减持
4
4.77万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-3.96%
制药与医学研究
-1.89%
高管信息
Chairman/Co-Founder/Director
Michel Lussier
Chief Executive Officer/Executive Director/Executive Board
Christian Homsy
Chief Financial Officer/Executive Board/Primary Contact
Patrick Jeanmart
Chief Operating Officer
Gaetane Metz
Vice President
Richard Mountfield
Vice President - Research & Development/Executive Board
Peter De Waele
Vice President - Business Development
Georges Rawadi
Other
Seron Aymeric
Other
Philippe Dechamps
Other
Roland Gordon-Beresford
Non-Executive Director
Serge Goblet
Non-Executive Director
Hanspeter Spek
Non-Executive Director
William Wijns
Independent Director
Chris Buyse
Independent Director
Rudy Dekeyser
  • 分红
  • 拆股
  • 内部人交易
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
暂无数据
CYAD 简况
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

微牛提供Celyad Oncology(NASDAQ-CYAD)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CYAD股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CYAD股票基本功能。